AVORO CAPITAL ADVISORS LLC 13D and 13G filings for Marinus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 09:34 am Sale |
2024-09-30 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
AVORO CAPITAL ADVISORS LLC | 0 0.000% |
-3,150,000 (Position Closed) |
Filing |
| 2024-02-14 09:04 am Unchanged |
2023-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
AVORO CAPITAL ADVISORS LLC | 3,150,000 5.800% |
0 (Unchanged) |
Filing |
| 2023-02-14 09:36 am Sale |
2022-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
AVORO CAPITAL ADVISORS LLC | 3,150,000 6.300% |
-85,000 (-2.63%) |
Filing |
| 2022-02-11 10:01 am Purchase |
2021-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
AVORO CAPITAL ADVISORS LLC | 3,235,000 8.800% |
2,858 (+0.09%) |
Filing |
| 2021-02-12 08:14 am Purchase |
2020-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
AVORO CAPITAL ADVISORS LLC | 3,232,142 9.090% |
3,232,142 (New Position) |
Filing |